Omanta GTM brain

Omanta assembles patient-specific scientific research programs for people with complex disease and their treating clinicians.

market profile

text: Patients with rare or treatment-refractory cancers can reach a point where applicable evidence or standard options are limited.
text: Patient-specific research combines records, molecular data and scientific literature to inform physician decisions; clinical outcomes are not guaranteed.

title: Patient with complex or treatment-refractory cancer
pains:
- Standard options may be exhausted or uncertain
- Medical records and relevant evidence are fragmented across providers
title: Caregiver or family advocate
pains:
- Coordinating records, testing and specialist input while navigating a difficult diagnosis
- Understanding which questions to raise with the treating team
title: Treating oncologist
pains:
- Limited time to synthesize fast-moving evidence for an unusual case
- Integrating pathology, imaging and molecular data into practical care decisions

text: Individual patients and families facing complex cancer, rare disease or unresolved diagnoses; this is a patient-centered market rather than a conventional firmographic ICP.
text: Oncology practices and specialist clinicians managing cases that need patient-specific evidence synthesis and diagnostic coordination; practice size is unspecified.

objection: Will this replace my doctor or guarantee a treatment?
response: Omanta describes working alongside physicians to inform decisions; ask the clinical team about evidence, limitations and care responsibility.
objection: What will it cost and is it covered?
response: Pricing and coverage are not publicly established in the sources reviewed; request a written case-specific estimate and coverage details.
objection: Can you access and protect sensitive medical data?
response: Ask for consent, privacy, record transfer and data-retention terms before sharing records.

name: Massive Bio
website: https://massivebio.com/
why: Cancer trial matching offers patients an alternative source of guidance on options.
name: OnconiX
website: https://www.onconix.com/
why: Patient-specific functional testing supports oncologists' treatment selection.
name: xCures
why: Precision oncology and trial matching overlap with parts of the patient navigation need.

text: A patient has exhausted standard options or seeks help with an unresolved diagnosis.
text: A treating clinician has an unusually complex case with fragmented clinical and molecular evidence.

model: unknown

sales_led

medium

name: Alfredo Gonzalez
title: Founder/CEO
role: CEO
bio: Co-Founder and CEO of Omanta. PhD in Cancer Bioinformatics from UCLA, biomedical researcher at Broad Institute and Harvard. Spearheaded personalized therapeutic campaigns for patients creating personalized vaccines, immunotherapies, and radioligands. 10+ years in personalized medicine. Fueled by the belief that the future of Health is deeply personalized.
name: Ranad Humeidi
title: Founder and Chief Scientific Officer
role: Founder
bio: Co-founder & CSO at Omanta, working with patients to turn frontier science into personalized treatment strategies. Harvard Chemical Biology PhD in 3 years; identified a druggable ulcerative colitis mechanism that led to a multimillion-dollar GSK collaboration. Built and directed a multimillion-dollar rare cancer program for one patient, coordinating researchers, physicians, biotechs, and drug developers. Led strategies for 12+ complex patients after standard options were exhausted.